Your browser doesn't support javascript.
loading
Next Generation Sequencing Should Be Proposed to Every Woman With "Idiopathic" Primary Ovarian Insufficiency.
Eskenazi, Sarah; Bachelot, Anne; Hugon-Rodin, Justine; Plu-Bureau, Genevieve; Gompel, Anne; Catteau-Jonard, Sophie; Molina-Gomes, Denise; Dewailly, Didier; Dodé, Catherine; Christin-Maitre, Sophie; Touraine, Philippe.
Affiliation
  • Eskenazi S; Department of Reproductive Endocrinology, Saint-Antoine Hospital, AP-HP, Paris, France; Center for Rare Growth Disorders and Center for Developmental Disorders: CMERC.
  • Bachelot A; Sorbonne University Medicine, Paris, France.
  • Hugon-Rodin J; Sorbonne University Medicine, Paris, France.
  • Plu-Bureau G; Department of Endocrinology and Reproductive Medicine, Pitié-Salpêtrière Hospital, AP-HP, Paris, France; Center for Rare Endocrine Disorders and Center for Rare Gynecological Disorders: CMERC.
  • Gompel A; Department of Gynecology and Endocrinology, Cochin/Port-Royal Hospital, AP-HP, Paris, France.
  • Catteau-Jonard S; Paris Descartes University, Paris, France.
  • Molina-Gomes D; INSERM UMR 1153, EPOPE group, Paris, France.
  • Dewailly D; Department of Gynecology and Endocrinology, Cochin/Port-Royal Hospital, AP-HP, Paris, France.
  • Dodé C; Paris Descartes University, Paris, France.
  • Christin-Maitre S; INSERM UMR 1153, EPOPE group, Paris, France.
  • Touraine P; Department of Gynecology and Endocrinology, Cochin/Port-Royal Hospital, AP-HP, Paris, France.
J Endocr Soc ; 5(7): bvab032, 2021 Jul 01.
Article in En | MEDLINE | ID: mdl-34095689
ABSTRACT
CONTEXT Primary ovarian insufficiency (POI) affects 1% of women under 40 years of age. POI is idiopathic in more than 70% of cases. Though many candidate genes have been identified in recent years, the prevalence and pathogenicity of abnormalities are still difficult to establish.

OBJECTIVE:

Our primary objective was to evaluate the prevalence of gene variations in a large prospective multicentric POI cohort. Our secondary objective was to evaluate the correlation between phenotype and genotype.

METHODS:

Two hundred and sixty-nine well-phenotyped POI patients were screened for variants of 18 known POI genes (BMP15, DMC1, EIF2S2, FIGLA, FOXL2, FSHR, GDF9, GPR3, HFM1, LHX8, MSH5, NOBOX, NR5A1, PGRMC1, STAG3, XPNPEP2, BHLB, and FSHB) by next generation sequencing (NGS). Abnormalities were classified as "variant" or "variant of unknown signification" (VUS) according to available functional tests or algorithms (SIFT, Polyphen-2, MutationTaster).

RESULTS:

One hundred and two patients (38%) were identified as having at least 1 genetic abnormality. Sixty-seven patients (25%) presented at least 1 variant. Forty-eight patients presented at least 1 VUS (18%). Thirteen patients (5%) had combined abnormalities. NOBOX variants were the most common gene variants involved in POI (9%). Interestingly, we saw no significant differences in the previous family history of POI, ethnic origin, age at onset of POI, primary amenorrhea, or secondary menstrual disturbances between the different genotypes.

CONCLUSION:

In our study, a high percentage of patients presented gene variants detected by NGS analysis (38%). Every POI patient should undergo NGS analysis to improve medical cares of the patients.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials / Prognostic_studies / Risk_factors_studies Language: En Journal: J Endocr Soc Year: 2021 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials / Prognostic_studies / Risk_factors_studies Language: En Journal: J Endocr Soc Year: 2021 Document type: Article